<- Go Home
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Market Cap
$158.8M
Volume
125.5K
Cash and Equivalents
$37.8M
EBITDA
-$54.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$762.0K
Profit Margin
100.00%
52 Week High
$3.28
52 Week Low
$1.23
Dividend
N/A
Price / Book Value
2.86
Price / Earnings
-3.20
Price / Tangible Book Value
2.86
Enterprise Value
$104.8M
Enterprise Value / EBITDA
-1.92
Operating Income
-$55.4M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$54.8M
Debt
$781.0K
Equity
$55.4M
Revenue
$762.0K
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium